Flywheel Secures $15 Million in Series B Funding
Flywheel, the leading data management platform for medical research and collaboration, announced it has secured $15 million in Series B funding.
@Flywheel_io raises $15M in Series B round to support researchers in the growing demand for faster, more efficient R&D of personalized healthcare applications.
The funding round is being co-led by Beringea, a transatlantic venture capital investor that seeks to create lasting success for rapidly scaling entrepreneurial companies, and 8VC, which is focused on building technology platforms that create long-term economic and societal value. Other investors include Novartis dRx Capital, Hewlett Packard Enterprise (HPE), Great North Labs, iSelect and Argonautic Ventures, which has deep knowledge and experience in the life sciences market.
Recommended AI News: Lumen and VMware Expand Partnership to Drive Rapid Innovation at the Edge
“Flywheel’s impressive list of client institutions and enthusiastic adoption by world leaders in clinical and academic research prove the platform’s transformative potential. Its value proposition is not only as a market disruptor but as a tool to change the way life science research is conducted and help make life-changing discoveries faster. We’re excited to be part of this fast-growing Midwest company and support the work of its passionately committed team,” said William Blake III, Vice President at Beringea.
With Flywheel’s cloud-based data management solution, organizations can streamline and scale their research and machine learning workflows. This funding will allow Flywheel to deepen its presence in the life sciences and AI markets and accelerate product development to power the digital transformation strategies of life sciences, clinical, and academic institutions globally.
Recommended AI News: Arista Delivers Multi-Domain Segmentation for Zero Trust Enterprise
“It is our strong belief that the leading life science institutions of the next decade will succeed by taking advantage of their biomedical data. Flywheel’s product is the best-in-class infrastructure to fulfill this vision,” said Francisco Gimenez, Partner at 8VC. “We are excited to support the company as they help support the future of bioscience R&D.”
“We are incredibly excited by the opportunities ahead for Flywheel as we enable healthcare and research organizations to accelerate innovation in imaging research, machine learning and clinical trials. This new round of funding will allow us to more quickly scale and grow our business to help more organizations improve scientific collaboration and accelerate discoveries that will change the way healthcare is delivered,” said Jim Olson, CEO, Flywheel.
Recommended AI News: tZERO Signs Agreement With Transfer Agent and Issuance Platform, Vertalo